Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir‐containing regimen
Christophe Hézode, Stéphane Chevaliez, Giovanna Scoazec, Alexandre Soulier, Anne Varaut, Magali Bouvier‐Alias, Isaac Ruiz, Françoise Roudot‐Thoraval, Ariane Mallat, Cyrille Féray, Jean‐Michel Pawlotsky – 8 February 2016 – Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct‐acting antiviral‐based regimens is commonly associated with emergence of resistance‐associated variants (RAVs).